CAMP4 Therapeutics Corporation has announced its financial results for the first quarter ended March 31, 2025. The company's cash, cash equivalents, and marketable securities totaled $49.3 million as of March 31, 2025, showing a decline from $64.0 million at the end of December 2024. Research and development expenses increased to $10.1 million from $9.7 million in the same quarter of the previous year, largely due to higher clinical and preclinical study costs. General and administrative expenses also rose to $3.8 million from $3.1 million, driven by increased personnel-related and overhead expenses. The net loss for the quarter was reported at $12.4 million, compared to a net loss of $12.5 million in the same period last year. In terms of corporate updates, CAMP4 achieved a milestone event in April 2025 under its July 2023 agreement with Fulcrum Therapeutics, making the company eligible for a $0.6 million payment. This agreement could potentially result in up to $70.0 million in development, regulatory, and sales milestone payments, in addition to royalties on global net sales. Furthermore, CAMP4 nominated a new development candidate, CMP-SYNGAP-01, for treating SYNGAP-1 related disorders based on promising preclinical data. The company has also completed dosing in the first three multiple ascending dose cohorts of its ongoing clinical trial of CMP-CPS-001 and submitted a CTA in Europe for a Phase 1b clinical trial targeting female OTC heterozygotes. These developments underscore CAMP4's continued momentum and the potential of their RAP Platform.